<DOC>
	<DOC>NCT00383292</DOC>
	<brief_summary>The primary purpose of this study is to determine the objective response rate (complete and partial response) for patients who receive LY573636 after one prior systemic treatment for unresectable or metastatic melanoma.</brief_summary>
	<brief_title>A Study of LY573636 in Treating Patients With Malignant Melanoma</brief_title>
	<detailed_description>Patients will receive a 2-hour intravenous infusion of study drug (LY573636) once every 28 days. Radiological imaging scans will be performed before the first dose of study drug and then after every other treatment. Patients will be assessed for clinical progression at every visit and for response approximately every 56 days (every other cycle).</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Diagnosis of malignant melanoma that is unresectable or metastatic (Stage III or IV) Have received 1 previous systemic treatment regimen for unresectable or metastatic melanoma. An immunotherapy or antibodybased regimen (including vaccinationbased treatments) is not counted as a prior treatment regimen for determining study eligibility, unless it was combined with a chemotherapeutic or targeted anticancer drug. Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, immunotherapy, or other investigational therapy for at least 30 days Serious preexisting medical conditions Have received two or more previous treatment regimens for unresectable or metastatic melanoma Have a second primary cancer (unless diseasefree to more than 2 years) Active treatment with Warfarin (Coumadin) Primary ocular or mucosal melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>